Search for content, post, videos

MedImmune forms development alliance with Sanofi Pasteur

jallal
Medimmune and Sanofi Pasteur have announced an agreement to develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV,) jointly. MEDI8897 is currently in a Phase IIb clinical trial in pr
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.